Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$20.3 - $31.75 $7.96 Million - $12.4 Million
-392,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$22.4 - $24.47 $8.78 Million - $9.59 Million
392,000 New
392,000 $8.78 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $97.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.